scholarly journals Clinical Practice of Ketogenic Parenteral Nutrition in Children With Epilepsy

Author(s):  
Aycan Ünalp ◽  
Gürkan Gürbüz ◽  
Zeynep Akışın

High-fat, low-carb ketogenic diets have been used around for over a century for the treatment of epilepsy. In recent years, the use of ketogenic diets traditionally used for the treatment of resistant pediatric epilepsies has expanded to include conditions ranging from refractory status epilepticus to febrile infection-related epilepsy syndrome. In such cases where the enteral route can not be used, it may be life-saving to consider the parenteral ketogenic diet. However, there are some points to be considered for proper and effective monitoring by starting this treatment effectively and reliably. The aim of this review is to increase the awareness of physicians and dieticians on this subject in the light of the case reports, studies and international clinical practice guide.

2021 ◽  
pp. 153575972199832
Author(s):  
Karnig Kazazian ◽  
Marissa Kellogg ◽  
Nora Wong ◽  
Krista Eschbach ◽  
Raquel Farias Moeller ◽  
...  

New-onset refractory status epilepticus (NORSE) is a rare clinical presentation of refractory status epilepticus (RSE) that occurs in people without active epilepsy or preexisting neurologic disorder. Febrile infection-related epilepsy syndrome (FIRES) is a subcategory of NORSE. New-onset refractory status epilepticus/FIRES are becoming increasingly recognized; however, information pertaining to disease course, clinical outcomes, and survivorship remains limited, and mortality and morbidity are variable, but often high. The objective of the NORSE/FIRES Family Registry is to (1) provide an easily accessible and internationally available multilingual registry into which survivors or NORSE/FIRES surrogates or family members of people affected by NORSE/FIRES or their physicians can enter data in a systematic and rigorous research study from anywhere in the world where internet is available; and (2) to examine past medical history, outcomes, and quality of life for people affected by NORSE/FIRES.


Neurology ◽  
2019 ◽  
Vol 92 (17) ◽  
pp. 802-810 ◽  
Author(s):  
Teneille E. Gofton ◽  
Nicolas Gaspard ◽  
Sara E. Hocker ◽  
Tobias Loddenkemper ◽  
Lawrence J. Hirsch

New-onset refractory status epilepticus (NORSE) is a clinical presentation, not a specific diagnosis, in a patient without active epilepsy or other preexisting relevant neurologic disorder, with new onset of refractory status epilepticus (RSE) that does not resolve after 2 or more rescue medications, without a clear acute or active structural, toxic, or metabolic cause. Febrile infection-related epilepsy syndrome is a subset of NORSE in which fever began at least 24 hours prior to the RSE. Both terms apply to all age groups. Until recently, NORSE was a poorly recognized entity without a consistent definition or approach to care. We review the current state of knowledge in NORSE and propose a roadmap for future collaborative research. Research investigating NORSE should prioritize the following 4 domains: (1) clinical features, etiology, and pathophysiology; (2) treatment; (3) adult and pediatric evaluation and management approaches; and (4) public advocacy, professional education, and family support. We consider international collaboration and multicenter research crucial in achieving these goals.


2021 ◽  
Vol 12 ◽  
Author(s):  
Natasha E. Schoeler ◽  
Zoe Simpson ◽  
Runming Zhou ◽  
Suresh Pujar ◽  
Christin Eltze ◽  
...  

Ketogenic diet therapies (KDT) are high-fat, low carbohydrate diets used as an effective treatment option for drug-resistant epilepsy. There is limited research on the efficacy of KDT for super-refractory status epilepticus (SRSE). We systematically review evidence for use of KDT in children with SRSE and present a single UK tertiary centre's experience. Thirty one articles were included, of which 24 were “medium” or “low” quality. One hundred and forty seven children with SRSE started KDT, of which 141 (96%) achieved ketosis. KDT was started mean 5.3 days (range 1–420) after status epilepticus (SE) started. SRSE resolved in 85/141 (60%) children after mean 6.3 days (range 0–19) post SE onset, but it is unclear whether further treatments were initiated post-KDT. 13/141 (9%) children died. Response to KDT was more likely when initiated earlier (p = 0.03) and in females (p = 0.01). Adverse side effects were reported in 48/141 (34%), mostly gastrointestinal; potentially serious adverse effects occurred in ≤4%. Eight children with SRSE, all diagnosed with febrile infection-related epilepsy syndrome, were treated with KDT at Great Ormond Street Hospital for Children. KDT was initiated enterally at mean day 13.6+/− 5.1 of admission. Seven of 8 (88%) children reported adverse side effects, which were potentially serious in 4/8 (50%), including metabolic acidosis, hypoglycaemia and raised amylase. SE ceased in 6/8 (75%) children after mean 25+/− 9.4 days post onset, but other treatments were often started concomitantly and all children started other treatments post-KDT. Two of 8 (25%) children died during admission and another died post-admission. Four of the remaining 5 children continue to have drug-resistant seizures, one of whom remains on KDT; seizure burden was unknown for one child. Our findings indicate that KDT is possible and safe in children with SRSE. Cessation of SRSE may occur in almost two-thirds of children initiated with KDT, but a causal effect is difficult to determine due to concomitant treatments, treatments started post-KDT and the variable length of time post-KDT onset when SRSE cessation occurs. Given that serious adverse side effects seem rare and response rates are (cautiously) favorable, KDT should be considered as an early treatment option in this group.


Epilepsia ◽  
2018 ◽  
Vol 59 (4) ◽  
pp. 745-752 ◽  
Author(s):  
Nicolas Gaspard ◽  
Lawrence J. Hirsch ◽  
Claudine Sculier ◽  
Tobias Loddenkemper ◽  
Andreas van Baalen ◽  
...  

2017 ◽  
Vol 01 (03) ◽  
pp. E204-E210
Author(s):  
Stephanie Gollwitzer ◽  
Hajo Hamer

AbstractRefractory status epilepticus (RSE) is defined as status epilepticus (SE) persisting over 60 min and resistant to treatment with benzodiazepines and non-sedating antiepileptic drugs. The term super-refractory status epilepticus (SRSE) refers to a refractory episode continuing under general anesthesia for more than 24 h. RSE is treated with a combination of non-sedating AED and i. v. anesthetics; first choice drugs are midazolam, propofol and thiopental. The management of super-refractory status epilepticus (SRSE) is challenging as clear evidence-based guidelines are lacking. Recommendations are mainly based on case reports and small case series. Therapeutic options include ketamine, inhalational anesthetics, steroids and immunoglobulins. Ketogenic diet, electroconvulsive therapy and epilepsy surgery are also considered as potentially effective. A promising new approach is the neurosteroid allopregnanolone. Mortality of RSE and SRSE is largely influenced by the etiology and is markedly higher as compared to non-refractory status epilepticus. It was reported to be about 30% and 50%, respectively.


Author(s):  
Armen K. Shakaryan ◽  
A. A. Kholin ◽  
N. V. Turkot ◽  
D. V. Shakhmaeva ◽  
I. V. Mitrofanova

Febrile infection-related epilepsy syndrome (FIRES) is an acute disease provoked by the nonspecific febrile illness with the development of refractory status epilepticus. It frequently occurs in previously healthy children. The pathogenesis of this syndrome is still unknown. The leading initial symptoms include acute fever, seizures, consciousness disorders and imitate neuroinfection or autoimmune pathology of CNS. These features make diagnosis extremely difficult, and there are in addition some difficulties with the verification of the diagnosis. Interpretation of MRI results allows identifying involved parts of the brain. However, the EEG record pattern is not precise. We report a clinical case of FIRES occurred in a 14-year-old previously healthy boy. The disease began similarly to an acute neuroinfection disease with prolonged refractory status epilepticus


Sign in / Sign up

Export Citation Format

Share Document